Recent Data on Anti-TROP2 ADCs for Patients With Advanced or Recurrent Endometrial Cancer
The panel highlights recent data on antibody drug conjugates targeting TROP2 in patients with advanced or recurrent endometrial cancer and the need for dose optimization.
EP: 1.Diagnosing and Staging Patients With Endometrial Cancer
EP: 2.Updated NCCN Guidelines for the Treatment of Advanced or Recurrent Endometrial Cancer
EP: 3.Shared Decision-Making in Advanced or Recurrent Endometrial Cancer
EP: 4.The Role of dMMR in the Progression of Endometrial Cancer
EP: 5.Dostarlimab Plus Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Cancer: Data from the RUBY Trial
EP: 6.The NRG-GY018 Trial: Pembrolizumab Plus Chemotherapy in Advanced Endometrial Cancer
EP: 7.Emerging Data on Combination Therapies in Advanced or Recurrent Endometrial Cancer
EP: 8.Advances in Anti-HER2 ADCs in Patients With Advanced or Recurrent Endometrial Cancer
Now Viewing
EP: 9.Recent Data on Anti-TROP2 ADCs for Patients With Advanced or Recurrent Endometrial Cancer
EP: 10.Future Directions in the Treatment of Advanced or Recurrent Endometrial Cancer
EP: 11.Staging and Biomarker Testing For Patients With Cervical Cancer
EP: 12.Recent Updates in NCCN Guidelines for the Treatment of Recurrent or Metastatic Cervical Cancer
EP: 13.Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer
EP: 14.Ocular Toxicity Management Strategies for Patients With Cervical Cancer Receiving ADCs
EP: 15.Clinical Trials Evaluating Tisotumab Vedotin in Patients with Recurrent or Metastatic Cervical Cancer
EP: 16.Emerging Data on Anti-HER2 ADCs in Patients With Cervical Cancer
EP: 17.Future Directions in the Treatment of Recurrent or Metastatic Cervical Cancer
Related Videos
Related Content
